<p>Cytek Biosciences（納斯達克：CTKB - 獲取免費報告）在週二發佈給投資者的研究報告中，Piper Sandler 的股票分析師將其目標價格從 8.00 美元下調至 7.50 美元，Benzinga 報道。該券商目前對該股票的評級為 “超配”。Piper Sandler 的目標價格暗示該股票當前價格有 57.40% 的上漲潛力。</p>
<p>其他分析師最近也發佈了關於該公司的研究報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Cytek Biosciences 股票的 “賣出（e+）” 評級。Zacks Research 在 11 月 4 日的報告中將 Cytek Biosciences 的股票評級從 “強力買入” 下調至 “持有”。兩位股票研究分析師給予該股票買入評級，三位給予持有評級，另外兩位給予賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，共識目標價格為 5.50 美元。</p>
<p>獲取 <strong>Cytek Biosciences</strong> 警報：</p>
<p><strong>閲讀我們關於 Cytek Biosciences 的最新報告</strong></p>
<h2>Cytek Biosciences 價格表現</h2>
<p>週二，CTKB 的股票上漲 0.02 美元，達到 4.77 美元。該公司的股票交易量為 438,435 股，而其平均交易量為 978,443 股。該股票的 50 日簡單移動平均為 3.95 美元，200 日簡單移動平均為 3.62 美元。該股票的市值為 6.0928 億美元，市盈率為-47.65，貝塔值為 1.33。Cytek Biosciences 的 12 個月低點為 2.37 美元，12 個月高點為 7.30 美元。</p>
<p>Cytek Biosciences（納斯達克：CTKB - 獲取免費報告）最後一次發佈季度財報是在 11 月 28 日。該公司報告本季度每股收益為 0.04 美元。Cytek Biosciences 的淨利潤率為-6.51%，股本回報率為-3.35%。該業務本季度的收入為 4048 萬美元。分析師預計 Cytek Biosciences 在本年度將發佈-0.06 美元的每股收益。</p>
<h2>機構投資者對 Cytek Biosciences 的看法</h2>
<p>幾家機構投資者和對沖基金最近修改了對 CTKB 的持股。Federated Hermes Inc.在第二季度將其在 Cytek Biosciences 的持股增加了 150.9%。Federated Hermes Inc.現在擁有 7221 股該公司的股票，價值 25,000 美元，此前在上個季度增持了 4343 股。Brooklyn Investment Group 在第一季度將其在 Cytek Biosciences 的持股增加了 992,200.0%。Brooklyn Investment Group 現在擁有 9923 股該公司的股票，價值 40,000 美元，此前在上個季度增持了 9922 股。Vanguard Personalized Indexing Management LLC 在第二季度購買了價值約 42,000 美元的 Cytek Biosciences 新股份。US Bancorp DE 在第一季度將其在 Cytek Biosciences 的持股增加了 9,698.2%。US Bancorp DE 現在擁有 10680 股該公司的股票，價值 43,000 美元，此前在上個季度增持了 10571 股。最後，Captrust Financial Advisors 在第二季度購買了價值約 43,000 美元的 Cytek Biosciences 新股份。機構投資者持有該公司 69.46% 的股票。</p>
<h2>Cytek Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Cytek Biosciences, Inc.是一家細胞分析解決方案公司，提供細胞分析工具，以促進生物醫學研究和臨牀應用的科學進步。它提供 aurora 和 northern lights 系統，這些是光譜流式細胞儀，通過利用多個激光的熒光特徵來區分單個細胞上的熒光標籤，從而提供細胞分析；以及 aurora 細胞分選系統，利用全光譜分析技術進一步拓寬細胞分析的潛在應用；aurora CS 系統；amnis imagestream 成像流式細胞儀；guava muse 細胞分析儀；guava easycyte 流式細胞儀；以及 orion 試劑雞尾酒製備系統。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票：Cytek Biosciences</li>
<li>寵物是大生意：4 只值得加入您投資組合的大型寵物股票</li>
<li>巴里克的黃金季度：提升回購和股息</li>
<li>異常交易量的股票：如何實時發現異常交易量股票</li>
<li>Nebius 與 Meta 合作——人工智能增長可能將股票推向新高</li>
<li>如何計算期權利潤</li>
<li>EVgo 的 37% 收入增長：忘掉汽車，買下加油站</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Cytek Biosciences 嗎？</h2>
<p>在您考慮 Cytek Biosciences 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Cytek Biosciences 並不在名單上。</p>
<p>雖然 Cytek Biosciences 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CTKB

<p>Piper Sandler 將 Cytek Biosciences (NASDAQ:CTKB) 的目標股價從 8.00 美元下調至 7.50 美元，同時維持 “增持” 評級。這意味着從當前價格 4.77 美元來看，潛在上漲幅度為 57.40%。其他分析師的評級則各有不同，平均共識為 “持有”，目標股價為 5.50 美元。Cytek 報告的季度收入為 4048 萬美元，淨利潤率為負 6.51%。機構投資者持有該公司 69.46% 的股份</p>

<p>Cytek Biosciences (NASDAQ:CTKB - Get Free Report) had its price target cut by stock analysts at Piper Sandler from $8.00 to $7.50 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. Piper Sandler's target price suggests a potential upside of 57.40% from the stock's current price.</p>
<div class="lb-trans"><p>Cytek Biosciences（納斯達克：CTKB - 獲取免費報告）在週二發佈給投資者的研究報告中，Piper Sandler 的股票分析師將其目標價格從 8.00 美元下調至 7.50 美元，Benzinga 報道。該券商目前對該股票的評級為 “超配”。Piper Sandler 的目標價格暗示該股票當前價格有 57.40% 的上漲潛力。</p>
</div><p>Other analysts have also recently issued research reports about the company. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Cytek Biosciences in a research report on Wednesday, October 8th. Zacks Research lowered shares of Cytek Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of &#34;Hold&#34; and a consensus target price of $5.50.</p>
<div class="lb-trans"><p>其他分析師最近也發佈了關於該公司的研究報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Cytek Biosciences 股票的 “賣出（e+）” 評級。Zacks Research 在 11 月 4 日的報告中將 Cytek Biosciences 的股票評級從 “強力買入” 下調至 “持有”。兩位股票研究分析師給予該股票買入評級，三位給予持有評級，另外兩位給予賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，共識目標價格為 5.50 美元。</p>
</div><p>Get <strong>Cytek Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cytek Biosciences</strong> 警報：</p>
</div><p><strong>Read Our Latest Report on Cytek Biosciences</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Cytek Biosciences 的最新報告</strong></p>
</div><h2>Cytek Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Cytek Biosciences 價格表現</h2>
</div><p>Shares of CTKB traded up $0.02 on Tuesday, reaching $4.77. The company's stock had a trading volume of 438,435 shares, compared to its average volume of 978,443. The stock's 50 day simple moving average is $3.95 and its two-hundred day simple moving average is $3.62. The stock has a market capitalization of $609.28 million, a P/E ratio of -47.65 and a beta of 1.33. Cytek Biosciences has a 12-month low of $2.37 and a 12-month high of $7.30.</p>
<div class="lb-trans"><p>週二，CTKB 的股票上漲 0.02 美元，達到 4.77 美元。該公司的股票交易量為 438,435 股，而其平均交易量為 978,443 股。該股票的 50 日簡單移動平均為 3.95 美元，200 日簡單移動平均為 3.62 美元。該股票的市值為 6.0928 億美元，市盈率為-47.65，貝塔值為 1.33。Cytek Biosciences 的 12 個月低點為 2.37 美元，12 個月高點為 7.30 美元。</p>
</div><p>Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last released its quarterly earnings results on Tuesday, November 28th. The company reported $0.04 earnings per share for the quarter. Cytek Biosciences had a negative net margin of 6.51% and a negative return on equity of 3.35%. The business had revenue of $40.48 million for the quarter. Analysts expect that Cytek Biosciences will post -0.06 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cytek Biosciences（納斯達克：CTKB - 獲取免費報告）最後一次發佈季度財報是在 11 月 28 日。該公司報告本季度每股收益為 0.04 美元。Cytek Biosciences 的淨利潤率為-6.51%，股本回報率為-3.35%。該業務本季度的收入為 4048 萬美元。分析師預計 Cytek Biosciences 在本年度將發佈-0.06 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Cytek Biosciences</h2>
<div class="lb-trans"><h2>機構投資者對 Cytek Biosciences 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of CTKB. Federated Hermes Inc. boosted its position in shares of Cytek Biosciences by 150.9% during the second quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock worth $25,000 after acquiring an additional 4,343 shares during the last quarter. Brooklyn Investment Group lifted its stake in Cytek Biosciences by 992,200.0% in the 1st quarter. Brooklyn Investment Group now owns 9,923 shares of the company's stock worth $40,000 after purchasing an additional 9,922 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Cytek Biosciences during the second quarter valued at about $42,000. US Bancorp DE grew its position in shares of Cytek Biosciences by 9,698.2% during the first quarter. US Bancorp DE now owns 10,680 shares of the company's stock valued at $43,000 after purchasing an additional 10,571 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in shares of Cytek Biosciences in the second quarter worth about $43,000. Institutional investors own 69.46% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近修改了對 CTKB 的持股。Federated Hermes Inc.在第二季度將其在 Cytek Biosciences 的持股增加了 150.9%。Federated Hermes Inc.現在擁有 7221 股該公司的股票，價值 25,000 美元，此前在上個季度增持了 4343 股。Brooklyn Investment Group 在第一季度將其在 Cytek Biosciences 的持股增加了 992,200.0%。Brooklyn Investment Group 現在擁有 9923 股該公司的股票，價值 40,000 美元，此前在上個季度增持了 9922 股。Vanguard Personalized Indexing Management LLC 在第二季度購買了價值約 42,000 美元的 Cytek Biosciences 新股份。US Bancorp DE 在第一季度將其在 Cytek Biosciences 的持股增加了 9,698.2%。US Bancorp DE 現在擁有 10680 股該公司的股票，價值 43,000 美元，此前在上個季度增持了 10571 股。最後，Captrust Financial Advisors 在第二季度購買了價值約 43,000 美元的 Cytek Biosciences 新股份。機構投資者持有該公司 69.46% 的股票。</p>
</div><h2>Cytek Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Cytek Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.</p>
<div class="lb-trans"><p>Cytek Biosciences, Inc.是一家細胞分析解決方案公司，提供細胞分析工具，以促進生物醫學研究和臨牀應用的科學進步。它提供 aurora 和 northern lights 系統，這些是光譜流式細胞儀，通過利用多個激光的熒光特徵來區分單個細胞上的熒光標籤，從而提供細胞分析；以及 aurora 細胞分選系統，利用全光譜分析技術進一步拓寬細胞分析的潛在應用；aurora CS 系統；amnis imagestream 成像流式細胞儀；guava muse 細胞分析儀；guava easycyte 流式細胞儀；以及 orion 試劑雞尾酒製備系統。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Cytek Biosciences</li>
<li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li>
<li>Barrick's Golden Quarter: Boosts Buyback and Dividend</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Nebius Partners With Meta—AI Growth Could Send Stock to New Highs</li>
<li>How to Calculate Options Profits</li>
<li>EVgo's 37% Revenue Growth: Forget the Car, Buy the Gas Station</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票：Cytek Biosciences</li>
<li>寵物是大生意：4 只值得加入您投資組合的大型寵物股票</li>
<li>巴里克的黃金季度：提升回購和股息</li>
<li>異常交易量的股票：如何實時發現異常交易量股票</li>
<li>Nebius 與 Meta 合作——人工智能增長可能將股票推向新高</li>
<li>如何計算期權利潤</li>
<li>EVgo 的 37% 收入增長：忘掉汽車，買下加油站</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CTKB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cytek Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Cytek Biosciences 嗎？</h2>
</div><p>Before you consider Cytek Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Cytek Biosciences 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Cytek Biosciences 並不在名單上。</p>
</div><p>While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cytek Biosciences 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cytek Biosciences（納斯達克代碼：CTKB）的目標價在派傑被下調至 7.50 美元